These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Perez EA; Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer RH; Fitts D Support Care Cancer; 1997 Jan; 5(1):31-7. PubMed ID: 9010987 [TBL] [Abstract][Full Text] [Related]
25. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint? Koizumi W; Tanabe S; Nagaba S; Higuchi K; Nakayama N; Saigenji K; Nonaka M; Yago K Chemotherapy; 2003 Dec; 49(6):316-23. PubMed ID: 14671433 [TBL] [Abstract][Full Text] [Related]
26. [Combination effect of granisetron plus corticosteroid for prevention of cisplatin-induced emesis: a cross-over study comparing methylprednisolone and dexamethasone]. Tanaka K; Sekine M; Serikawa T; Sanada H; Shichiri K; Fujimori R Gan To Kagaku Ryoho; 1998 May; 25(6):907-13. PubMed ID: 9617330 [TBL] [Abstract][Full Text] [Related]
27. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting. Voravud N; Sriuranpong V J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975 [TBL] [Abstract][Full Text] [Related]
28. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Gebbia V; Cannata G; Testa A; Curto G; Valenza R; Cipolla C; Latteri MA; Gebbia N Cancer; 1994 Oct; 74(7):1945-52. PubMed ID: 8082100 [TBL] [Abstract][Full Text] [Related]
29. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy. Massidda B; Ionta MT J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140 [TBL] [Abstract][Full Text] [Related]
31. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415 [TBL] [Abstract][Full Text] [Related]
32. Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis--JCOG study 9413. Sekine I; Nishiwaki Y; Kakinuma R; Kubota K; Hojo F; Matsumoto T; Ohmatsu H; Yokozaki M; Goto K; Miyamoto T; Takafuji J; Kodama T Br J Cancer; 1997; 76(1):90-2. PubMed ID: 9218738 [TBL] [Abstract][Full Text] [Related]
33. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research. Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965 [TBL] [Abstract][Full Text] [Related]
34. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. Hesketh PJ; Gralla RJ; Webb RT; Ueno W; DelPrete S; Bachinsky ME; Dirlam NL; Stack CB; Silberman SL J Clin Oncol; 1999 Jan; 17(1):338-43. PubMed ID: 10458252 [TBL] [Abstract][Full Text] [Related]
35. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy. Bhatia A; Tripathi KD; Sharma M Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464 [TBL] [Abstract][Full Text] [Related]
36. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis. Martoni A; Piana E; Strocchi E; Angelelli B; Guaraldi M; Zamagni C; Camaggi CM; Pannuti F Anticancer Res; 1998; 18(4B):2799-803. PubMed ID: 9713464 [TBL] [Abstract][Full Text] [Related]
37. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Kleisbauer JP; García-Girón C; Antimi M; Azevedo MC; Balmes H; Massuti-Sureda B; Contu A; Luque A; Pellier P Anticancer Drugs; 1998 Jun; 9(5):387-92. PubMed ID: 9660534 [TBL] [Abstract][Full Text] [Related]
38. Randomised double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Garcia-del-Muro X; Vadell C; Pérez Manga G; Bover I; Rifá J; Beltrán M; Barros MM; Germá JR; Fabregat X; Moreno V; Salvador A; Viladiu P Eur J Cancer; 1998 Jan; 34(1):193-5. PubMed ID: 9624257 [TBL] [Abstract][Full Text] [Related]
39. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358 [TBL] [Abstract][Full Text] [Related]
40. Oral cisapride for the control of delayed vomiting following high-dose cisplatin. Pizzo BA; Pisters KM; Miller VA; Grant SC; Baltzer L; Hinckley L; Kris MG Support Care Cancer; 1999 Jan; 7(1):44-6. PubMed ID: 9926974 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]